NCI’s Office of Cancer Survivorship: Celebrating 20 Years, Planning for Continued Progress

| February 15, 2017 | 0 Comments
NCI’s Office of Cancer Survivorship: Celebrating 20 Years, Planning for Continued Progress

Dr. Julia Rowland, director of NCI’s Office of Cancer Survivorship, on the office’s 20th anniversary and efforts to ensure continued progress in survivorship research and improve survivors’ lives.
See Original Article

Crizotinib Approval Expanded for Advanced Lung Cancer

The FDA has approved uses of the targeted therapy crizotinib (Xalkori®) for patients with advanced lung cancer whose tumors have alterations in the ROS1 gene.
See Original Article

Anthrax Toxin-Based Cancer Therapy Targets Tumor Blood Vessels

A therapy that uses the anthrax toxin selectively targets blood vessels that feed tumors and support their growth and spread, researchers have found.
See Original Article

Category: Recent News

About the Author ()

Leave a Reply